Aberrant activation of β-catenin, often due to mutations in its encoding gene or loss-of-function mutations in APC, contributes to tumor progression and therapy resistance, as seen in advanced hepatocellular carcinoma (HCC), where approximately 30% of cases exhibit β-catenin activation.